Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Sorafenib in Combination With Local Micro-therapy Guided by Gd-EOB-DTPA Enhanced MRI in Patients With Inoperable Hepatocellular Carcinoma

Next Previous
Trial Profile

Evaluation of Sorafenib in Combination With Local Micro-therapy Guided by Gd-EOB-DTPA Enhanced MRI in Patients With Inoperable Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Gadoxetate disodium; Yttrium-90
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SORAMIC

    • Most Recent Events

    • 15 Aug 2022 Results of post-hoc analysis assessing prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in patients with advanced HCC receiving sorafenib, published in the Journal of Cancer Research and Clinical Oncology.
    • 26 Aug 2021 Results (n=282) assessing the outcome of patients receiving selective internal radiation therapy (SIRT) + sorafenib versus sorafenib alone was affected by adverse effects of SIRT on liver function, published in the Journal of Hepatology.
    • 14 Aug 2019 Results comparing the efficacy and safety of a combination of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres and sorafenibin patients with advanced HCC published in the Journal of Hepatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top